Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health (NYSE: EVH) announces the appointment of Dr. Tunde Sotunde to its Board of Directors, bringing over 20 years of healthcare experience. Dr. Sotunde, currently CEO of Blue Cross and Blue Shield of North Carolina, replaces Michael D'Amato, who is retiring. His leadership at Anthem, where he oversaw Medicaid efforts serving 7.3 million members and generating $33 billion in revenue, underscores his expertise. Additionally, effective January 1, 2022, Frank Williams transitions from Executive Chairman to non-executive Chairman, reflecting the company's governance evolution.
Evolent Health (NYSE: EVH) announced a partnership with Health New England to provide advanced care planning services via its subsidiary, New Century Health. The initiative, utilizing the Vital Decisions platform, aims to support Health New England's 180,000 members in articulating their healthcare preferences during serious illness. Through personalized consultations, the Living Well program allows patients to document their care goals, ensuring that their choices are reflected in medical plans. This partnership seeks to empower patients and enhance their healthcare experience.
Evolent Health, Inc. (NYSE: EVH) reported third-quarter 2021 financial results, revealing GAAP revenue of $222.5 million, a 7.1% decrease from the previous year. Excluding divested assets, revenue grew 36.3%. The net loss for common shareholders was $(13.0) million, with an adjusted EBITDA of $13.8 million. Total lives managed reached 14.7 million. The company announced new partnerships, exceeding its target of ten for 2021. Full year revenue guidance is revised to $884-$900 million, with adjusted EBITDA expected between $56-$60 million.
Evolent Health (NYSE: EVH) will announce its third quarter 2021 operating results on November 3, 2021, after market close. A conference call is scheduled for 5:30 p.m. Eastern Time the same day. Interested participants can join by calling 855.940.9467 or 412.317.6034 for international listeners, mentioning the "Evolent Health call" 15 minutes prior. The call will also be available for playback on Evolent's investor relations website for a week post-call. Evolent Health specializes in health care solutions aimed at improving affordability and simplifying care delivery.
On October 6, 2021, WindRose Health Investors announced the sale of Vital Decisions, a provider of technology-enabled advance care-planning services, to Evolent Health (NYSE: EVH). This acquisition positions Vital Decisions under Evolent's specialty management division, New Century Health, thus integrating into Evolent’s Clinical Solutions segment. Vital Decisions aims to ensure individuals' healthcare aligns with their values using advanced methodologies and analytics. WindRose had partnered with Vital Decisions since 2012, resulting in significant growth.
Evolent Health, Inc. (NYSE: EVH) announced participation in upcoming investor conferences by CEO Seth Blackley and CFO John Johnson. They will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 3:30 p.m. ET, with a live webcast available on Evolent's website. Additionally, they will present at the 2021 Cantor Global Healthcare Conference on September 27, 2021, at 9:20 a.m. ET. Evolent is known for delivering clinical and administrative solutions that improve health care efficiency and affordability.
Evolent Health, Inc. (NYSE: EVH) announced its acquisition of Vital Decisions from WindRose Health Investors for $85 million, with potential earn-outs up to $45 million. This strategic acquisition aims to integrate Vital Decisions' technology-enabled advance care planning services into Evolent's Clinical Solutions segment, enhancing patient engagement and care alignment. The deal is expected to provide significant clinical and financial synergies while being accretive to EBITDA per share. The transaction is projected to close later this year, pending regulatory approvals.
Evolent Health, Inc. (NYSE: EVH) reported financial results for Q2 2021, achieving GAAP revenue of $222.1 million, a 2.2% increase year-over-year. Organic revenue growth was notably high at 42.3%. However, the company recorded a net loss of $(9.1) million. Adjusted EBITDA rose to $13.3 million, up $2.8 million from Q2 2020. Evolent announced key acquisitions and partnerships that reflect a strategic push for growth, including the acquisition of Vital Decisions. The company also raised its full-year revenue guidance to $870-$900 million.
Evolent Health (NYSE: EVH) will have CEO Seth Blackley and CFO John Johnson present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 12:00 p.m. ET. A live webcast of the event will be available on Evolent's investor relations website. Evolent Health specializes in delivering clinical and administrative solutions to enhance healthcare affordability and manage total costs. The company has received the Population Health Program Accreditation and is recognized as a leader in healthcare service delivery.
Evolent Health (NYSE: EVH) will announce its second quarter 2021 operating results on August 4, 2021, after the market closes. A conference call will take place at 6:00 p.m. Eastern Time the same day, allowing shareholders to participate via phone. Evolent Health specializes in clinical and administrative healthcare solutions aimed at improving total care management. The company has achieved notable accreditations and is recognized for its workplace culture.